Press-release for stocks related to vaccine for vbiv

Prices are updated after-hours

tags : Vaccine symbols : Vbiv

save search

VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
Published: 2024-04-02 (Crawled : 14:30) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K

Health Technology

| Email alert Add to watchlist
partnership vaccine platform

VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program
Published: 2023-10-26 (Crawled : 14:00) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K

Health Technology

| 27.02% | O: 0.81% H: 28.0% C: 20.8%
vaccine program technology

VBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern
Published: 2023-09-27 (Crawled : 13:00) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K

Health Technology

| 0.64% | O: 8.63% H: 8.82% C: -1.68%
vbi-2901 vaccine

VBI Vaccines Announces Health Canada Approval for PreHevbrio™ for the Prevention of Hepatitis B in Adults
Published: 2022-12-08 (Crawled : 15:20) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K

Health Technology

| -95.85% | O: 0.79% H: 12.25% C: 2.24%
hepatitis canada health approval vaccine

VBI Vaccines to Participate in Upcoming Investor Conferences - November 14, 2022
Published: 2022-11-14 (Crawled : 14:20) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K

Health Technology

| -96.48% | O: 0.45% H: 6.67% C: 3.33%
vaccine

VBI Vaccines Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Published: 2022-11-10 (Crawled : 14:20) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K

Health Technology

| -96.53% | O: -0.73% H: 11.01% C: -1.16%
financial update results vaccine

VBI Vaccines to Participate in H.C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference
Published: 2022-10-17 (Crawled : 14:00) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K

Health Technology

| -96.8% | O: 2.13% H: 2.99% C: 0.6%
hepatitis conference virus vaccine

VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901
Published: 2022-09-29 (Crawled : 13:00) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K

Health Technology

| -97.32% | O: -2.08% H: 0.31% C: -4.82%
vbi-2901 vaccine study phase 1

VBI Vaccines Announces Presentation of Physician-Initiated Compassionate Use Data of its 3-Antigen Hepatitis B Vaccine at the 2022 International HBV Meeting
Published: 2022-09-21 (Crawled : 12:20) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K

Health Technology

| -97.24% | O: 1.7% H: 3.26% C: -1.36%
hepatitis meeting vaccine presentation international

VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures
Published: 2022-09-15 (Crawled : 13:00) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K

Health Technology

| -97.38% | O: 3.75% H: 2.4% C: -0.86%
vaccine

Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®
Published: 2022-09-08 (Crawled : 06:00) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K

Health Technology

| -97.61% | O: 1.34% H: 0.94% C: -0.67%
prehevbri valneva partnership distribution vaccine

VBI Vaccines Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Published: 2022-08-08 (Crawled : 13:00) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K

Health Technology

| -98.02% | O: -9.43% H: 12.5% C: 8.33%
update results vaccine

VBI Vaccines Announces Appointment of John Dillman as Chief Commercial Officer
Published: 2022-07-12 (Crawled : 13:00) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K

Health Technology

| -97.33% | O: 1.27% H: 6.58% C: 4.65%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -8.1% | O: -0.33% H: 0.0% C: 0.0%
commercial vaccine

VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022
Published: 2022-06-28 (Crawled : 13:00) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K

Health Technology

| -31.36% | O: -6.85% H: 1.74% C: -7.07%
hepatitis vaccine

VBI Vaccines Receives U.S. FDA Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma
Published: 2022-06-22 (Crawled : 12:20) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K

Health Technology

| -9.1% | O: 8.21% H: 26.11% C: 16.65%
vbi-1901 treatment fda designation drug vaccine glioblastoma

VBI Vaccines to Participate in the Jefferies Healthcare Conference
Published: 2022-06-07 (Crawled : 13:20) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K

Health Technology

| -29.21% | O: 3.3% H: 6.59% C: 5.31%
conference vaccine

VBI Vaccines Announces UK MHRA Marketing Authorisation for PreHevbri™, a 3-Antigen Adult Hepatitis B Vaccine
Published: 2022-06-01 (Crawled : 12:20) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K

Health Technology

| -32.26% | O: 2.24% H: 1.97% C: -7.08%
hepatitis vaccine

VBI Vaccines Announces Abstract Accepted for Oral Presentation at EASL 2022
Published: 2022-05-26 (Crawled : 13:00) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K

Health Technology